Fig. 4
Comparison of Kaplan-Meier curves of progression-free survival and cancer-specific survival of metastatic renal cell carcinoma patients with treatment-free intervals ≥1 year and with synchronous metastases (a–b) and metachronous metastases (c-d) between patients receiving immunotherapy (IT) and targeted therapy (TT); shown are intermediate-risk patients according to the Heng criteria